Treatment of Pituitary Neuroendocrine Tumors
Surgery is the first-line treatment for symptomatic pituitary neuroendocrine tumors (PitNETs), with the exception of prolactinomas which should be treated with dopamine agonists (cabergoline or bromocriptine). 1, 2
Treatment Algorithm by Tumor Type
Functioning (Hormone-Secreting) Tumors
Prolactinomas (32-66% of all PitNETs):
- Start with dopamine agonists (cabergoline preferred over bromocriptine) as primary therapy 2
- Surgery is reserved for medication failures or intolerance
- These are the ONLY pituitary tumors where medical therapy is first-line
Growth Hormone-Secreting Tumors (8-16%):
- Primary treatment is transsphenoidal surgery 2
- Medical therapy with somatostatin analogues, cabergoline, or pegvisomant is added postoperatively if not cured surgically
- Goal is biochemical remission (normalized IGF-1 and growth hormone levels)
ACTH-Secreting Tumors/Cushing Disease (2-6%):
- Primary treatment is surgical adenoma resection 2
- Medical therapies (ketoconazole, mifepristone, pasireotide) are used for surgical failures
- Petrosal sinus sampling may be needed to confirm pituitary source before surgery
TSH-Secreting Tumors (1%):
- Surgery followed by somatostatin analogues if not cured 2
Non-Functioning Pituitary Adenomas (NFPAs)
Absolute surgical indications: 1, 3
- Visual compromise, cranial neuropathy, or neurological deficit from mass effect
- Tumor abutting the optic chiasm (after evaluation at pituitary center)
- Severe/progressive vision loss from apoplexy
- Progressively enlarging macroadenomas, especially near optic chiasm
Relative surgical indications: 1
- Macroadenomas in young patients (<65 years)
- Evidence of tumor growth on serial MRIs
- Cavernous sinus invasion
- Women desiring pregnancy
- New-onset hypopituitarism (though postoperative recovery not assured)
Observation is appropriate for: 1
- Asymptomatic microadenomas
- Macroadenomas ≥5mm from optic chiasm in older patients (>65 years) or those with poor functional status
- Frail patients with asymptomatic macroadenomas
Surgical Approach
Endoscopic endonasal transsphenoidal surgery (eTSS) is the standard surgical technique 4, 5:
- For enclosed, non-invasive functioning tumors: pursue selective total resection with extracapsular dissection
- For large invasive tumors: maximal safe debulking followed by adjuvant therapy
- Cavernous sinus invasion is the most significant predictor of unfavorable outcomes 4
- Immediate tumor volume reduction occurs in nearly all patients with residual tumor rates of 10-36% 3
- Visual function improves in 75-91% of surgically treated patients 3
- Hypopituitarism improves in 35-50% of patients 3
Adjuvant Therapies
Radiation therapy (stereotactic radiosurgery or fractionated radiotherapy): 6
- Reserved for large tumor remnants after surgery
- Tumor recurrence following surgical attempts
- Radiographic tumor control ~90% for non-functioning adenomas
- Lower biochemical remission rates for functioning adenomas (highest in Cushing's disease, lowest in prolactinomas)
- Most common complication: delayed hypopituitarism, followed by cranial neuropathies
Medical therapy for NFPAs has limited role: 3
- Somatostatin analogs show only 12-40% response rate
- Dopamine agonists show 0-61% response rate
- Not recommended as primary treatment
Critical Pitfalls to Avoid
- Do not treat prolactinomas surgically first - dopamine agonists are dramatically more effective and should always be tried first 2
- Do not delay surgery in patients with visual compromise - visual outcomes worsen with delayed intervention 1, 3
- Do not assume age >65 years automatically excludes surgery - functional status and visual function matter more than chronological age 1
- Do not rely on medical therapy alone for non-functioning adenomas - evidence shows inconsistent benefits and 50% tumor progression with observation alone requiring surgery in 21% 3
Follow-Up Requirements
For macroadenomas not immediately operated: 1
- Visual field testing at 6 months if suprasellar extension present
- Visual field testing at 1-2 years for all macroadenomas
- Annual MRIs with visual field testing at 6-12 months between scans
- Refer abnormal visual fields to neuro-ophthalmologist